DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021" report to their offering.
The analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.
Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.
One driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
Other prominent vendors
- Sun Pharmaceutical Industries
- Teva Pharmaceutical
- The Medicines Company
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Disease overview
Part 06: Market landscape
Part 07: Pipeline analysis
Part 08: Market segmentation by drug class
Part 09: Geographical segmentation
Part 10: Decision framework
Part 11: Drivers and challenges
Part 12: Market trends
Part 13: Vendor landscape
Part 14: Key vendor analysis
Part 15: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/rcksz5/global